Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Solvonis Therapeutics Logo
Solvonis Therapeutics Growth Score
53
CB Rank
552641
Heat Score
55
Solvonis Therapeutics is a biopharmaceutical firm developing treatments for addiction and mental health issues.
Public London, England, United Kingdom1-10 solvonis.com
Biotechnology
Medical
Pharmaceutical
Overview

Solvonis Therapeutics
Growth Score
53
Heat Score
55

Growth Score53
-26 pts
in past quarter
Heat Score 55
-23 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Solvonis Therapeutics

CB Rank
552641
Solvonis Therapeutics is a biopharmaceutical firm developing treatments for addiction and mental health issues.
Public London, England, United Kingdom1-10 solvonis.com
Biotechnology
Medical
Pharmaceutical

Details

Legal Name Solvonis Therapeutics Plc
Also Known As Graft Polymer (UK)
Operating Status Active
Stock Symbol  LSE:SVNS
Company Type For Profit
About the Company
Solvonis Therapeutics is a clinical-stage biopharmaceutical firm developing treatments for addiction and mental health issues.
Contact Email info@solvonis.com
Predictions & Insights

Growth Insight

See this Growth Insight
Solvonis Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

SVN-001
A Phase 3 combination therapy using IV ketamine and cognitive behavioural therapy to treat severe alcohol use disorder in the UK and EU.
SVN-002
A novel therapy combining esketamine oral thin film with psycho-social support to treat moderate to severe alcohol use disorder in the US.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News

News and Press

News•Feb 15, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 3, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 3, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Aug 13, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

115
-96.23%
 in past month

IT Spend

$101.2KThis year, Solvonis Therapeutics is projected to spend $101.2K on IT, according to Aberdeen.

Total IP

2Solvonis Therapeutics has registered 2 trademarks with the most popular class being 'Chemical substances', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Solvonis Therapeutics's headquarters? Solvonis Therapeutics is located in London, England, United Kingdom.Who are Solvonis Therapeutics's competitors? Alternatives and possible competitors to Solvonis Therapeutics may include Seaport Therapeutics, BnH Research, and  Virpax Pharmaceuticals Inc..
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(55a1db1 1)
|